###### Strengths and limitations of this study

-   Routine data sources will also include missing data and measurements taken with varying periodicity.

-   Owing to the nature of routine data, it was not possible to measure discrete stages of retinopathy.

-   Confounding by indication may remain a source of bias.

Introduction {#s1}
============

Diabetic retinopathy (DR) remains a common diabetic complication globally, with an overall diabetes prevalence of approximately 35%, varying according to the type of diabetes, ethnicity, diabetes duration, glycaemic control and blood pressure.[@R1] In the UK, approximately 40% of people with type 2 diabetes are reported to have DR.[@R2] In severe cases, DR can result in blindness and represents the leading cause of blindness and visual disability in the non-elderly population.[@R3] Furthermore, as the prevalence of diabetes has increased, rates of blindness attributed to DR have correspondingly increased.[@R4]

Early detection of DR in individuals with diabetes is critical in preventing visual loss and, consequently, DR screening programmes have been introduced throughout the UK.[@R5; @R6; @R7] The control of diabetes-associated metabolic abnormalities such as dyslipidaemia is also considered important in preventing the progression of DR in people with type 2 diabetes.[@R8] Recently, fenofibrate has shown promise in delaying DR progression in people with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and The Action to Control Cardiovascular Risk in Diabetes (ACCORD) randomised controlled trials.[@R9] [@R10]

In this study, we aimed to compare the rates of new onset of DR (first diagnosis of DR) in people with type 2 diabetes treated with fibrates and in matched non-exposed controls using UK population-based routine data.

Methods {#s2}
=======

This retrospective, matched cohort study used data from the Clinical Practice Research Datalink (CPRD): a longitudinal, anonymised database derived from nearly 700 primary care practices throughout the UK that are broadly geographically and demographically representative of the country as a whole.[@R11] At the time of the study, CPRD contained clinical records from over 11 million people. The data captured by CPRD include demographics, medical history, clinical investigations and drug prescriptions. The routine data are recorded electronically in general practice and monitored for quality by the UK Medicines and Healthcare products Regulatory Agency (MHRA). Diagnoses in CPRD are recorded using the Read code classification and have been validated in a number of studies, showing a high positive predictive value.[@R12]

Subject selection {#s2a}
-----------------

Study participants were classified as having type 2 diabetes if they had a diagnosis of diabetes and any of the following: More than one diagnostic record exclusively for type 2 diabetes OR;Prescription of two or more differing classes of oral antidiabetic drugs (OADs) OR;A diagnostic code indicative of type 2 diabetes (regardless of conflicting diagnoses of type 1 or non-specific diabetes) plus a prescription for an OAD.

Only those with a minimum of 180 days between practice registration and first diabetes presentation were included.

Identification of individuals with fibrate therapy {#s2b}
--------------------------------------------------

People initiating fibrate therapy following diabetes diagnosis were selected as the exposed group. Those participants with a DR event dated before the date of first fibrate or the date of diabetes presentation were excluded since this was a primary prevention study.

Matching of controls {#s2c}
--------------------

Each member of the exposed cohort was matched at random with one person from the remaining diabetes population using the following criteria: gender, year of birth (±2 years), smoking status, duration of diabetes (±6 months), registration with a differing general practice (to minimise confounding by indication), prior statin use, systolic blood pressure (±5 mm Hg) and glycated haemoglobin (HbA1c; ±0.5%). Where either systolic blood pressure or HbA1c was missing, participants were matched on a control with the same missing value. The index date for the exposed patients was the date of first fibrate exposure.

Study endpoints {#s2d}
---------------

The primary endpoint for this study was first-recorded diagnosis of DR within the CPRD dataset. Relevant diagnoses and procedures as recorded by Read code in CPRD were assessed and identified by two clinicians experienced in diabetes-related eye disease. To investigate for competing risks, time to all-cause mortality and a combined endpoint of all-cause mortality or first DR were also characterised.

Statistical analysis {#s2e}
--------------------

Descriptive analysis was performed, providing mean (SD) values for continuous variables and proportions for categorical variables. Time to clinical endpoints was compared using Cox proportional hazards models from index date to date of event or censorship. The selected potential covariates included age, gender, systolic blood pressure, baseline HbA1c, total cholesterol, body mass index and smoking status. Baseline morbidity was characterised in three ways: (1) history for each of cancer, large vessel disease, renal failure and visual deterioration; (2) the number of primary care contacts in the year prior to the index date; and (3) Charlson comorbidity index.[@R13] Covariates were included in the final model where p\<0.20. Participants with missing data were excluded automatically and the proportional hazards assumption was considered using evaluation of the Kaplan-Meier curves and analysis of the Schoenfeld residuals. Mean HbA1c per year with last observation carried forward was also modelled as a time-dependent variable.

Results {#s3}
=======

Subjects and baseline characteristics {#s3a}
-------------------------------------

We identified 5038 eligible participants with a first exposure to fibrates. Three thousand one hundred and seventy-six (63%) could be matched to one control, and, of these, 2599 (81.8%) could be matched without any missing blood pressure or HbA1c values.

Baseline characteristics are detailed in [table 1](#BMJOPEN2013004025TB1){ref-type="table"}. There were significant differences between those exposed and not exposed to fibrates for total cholesterol (5.6 vs 4.7 mmol/L), high-density lipoprotein cholesterol (1.1 vs 1.3 mmol/L), low-density lipoprotein cholesterol (3.1 vs 2.6 mmol/L), triglycerides (3.2 vs 1.9 mmol/L) and primary care contacts in the preceding year (13.4 vs 12.6 consultations).

###### 

Baseline characteristics for all fibrate-exposed and matched fibrate and non-exposed controls

  Parameter                                          All fibrate patients   Fibrate matched   Non-exposed controls                               
  -------------------------------------------------- ---------------------- ----------------- ---------------------- --------- ------- --------- ---------
  n                                                  5038                   3176              3176                                               
  Follow-up (years) (mean, SD)                       5.2                    (3.2)             5.1                    (3.2)     5.0     (3.2)      
  Matched variables                                                                                                                               
   Age on index date (years) (mean, SD)              60.9                   (11.8)            61.8                   (10.7)    61.8    (10.7)     
   Age on diabetes presentation (years) (mean, SD)   57.1                   (11.7)            58.5                   (10.4)    58.6    (10.5)     
   Females (n,%)                                     2203                   (43.7%)           1295                   (40.8%)   1295    (40.8%)    
   Duration of diabetes (years) (mean, SD)           3.9                    (3.8)             3.2                    (3.0)     3.3     (3.0)      
   Systolic BP (mm Hg) (mean, SD)                    137.8                  (16.5)            136.5                  (13.4)    136.5   (13.4)     
   HbA1c (%, SD)                                     7.4                    (1.6)             7.1                    (1.2)     7.1     (1.1)      
   Prior statin use (n,%)                            3781                   (75.0%)           2307                   (72.6%)   2307    (72.6%)    
  Unmatched variables                                                                                                                            p Value
   BMI (kg/m^2^) (mean, SD)                          31.1                   (5.4)             30.7                   (5.7)     30.6    (6.1)     0.330
   Diastolic BP (mm Hg) (mean, SD)                   79.4                   (9.5)             78.9                   (9.1)     78.7    (9.1)     0.222
   Total cholesterol (mmol/L) (mean, SD)             5.6                    (1.3)             5.6                    (1.4)     4.7     (1.1)     \<0.001
   HDL (mmol/L) (mean, SD)                           1.2                    (0.4)             1.1                    (0.4)     1.3     (0.4)     \<0.001
   LDL (mmol/L) (mean, SD)                           3.1                    (1.2)             3.1                    (1.2)     2.6     (0.9)     \<0.001
   Triglycerides (mmol/L) (mean, SD)                 3.7                    (2.4)             3.2                    (1.6)     1.9     (1.0)     \<0.001
   GP contacts in preceding year (mean, SD)          13.9                   (10.2)            13.4                   (9.9)     12.6    (10.3)    0.001
   Charlson index (mean, SD)                         1.9                    (1.3)             2.0                    (1.4)     2.0     (1.4)     0.404

BMI, body mass index, BP, blood pressure; GP, general practitioner, HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

The most commonly used fibrate was bezafibrate, used by 1739 patients (54.8%; [table 2](#BMJOPEN2013004025TB2){ref-type="table"}), followed by fenofibrate used by 1413 patients (44.5%; [table 2](#BMJOPEN2013004025TB2){ref-type="table"}). The mean duration of fibrate therapy was 2.6 years (SD 2.8); median duration was 2.3 years (95% CI 2.0 to 2.5). Of note, fenofibrate was the fibrate with the longest use (mean duration 2.8 years; [table 2](#BMJOPEN2013004025TB2){ref-type="table"}). Time to discontinuation is shown in [figure 1](#BMJOPEN2013004025F1){ref-type="fig"}.

###### 

Frequency and mean duration of specific fibrate use during follow-up period

  Fibrate        Number\*   Mean treatment duration (years)
  -------------- ---------- ---------------------------------
  Bezafibrate    1739       2.1
  Fenofibrate    1413       2.8
  Ciprofibrate   187        2.3
  Gemfibrozil    67         2.0
  Clofibrate     1          0.1
  Any fibrate    3176       2.6

\*Patients may have received more than one type of fibrate during follow-up.

![Time to discontinuation of fibrate.](bmjopen2013004025f01){#BMJOPEN2013004025F1}

Crude event rates {#s3b}
-----------------

Four hundred and eighty-nine (15.4%) patients exposed to fibrates developed a newly detected retinopathy compared with 569 (17.9%) of those non-exposed. This represented a reduction in newly detected DR (33.4 events/1000 person-years vs 40.4 in non-exposed individuals; p=0.002) and in death or DR (50.6 vs 60.2, p\<0.001; [table 3](#BMJOPEN2013004025TB3){ref-type="table"}). For participants matched with full systolic blood pressure and HbA1c data, the respective rate of DR was 34.3 events/1000 person-years for those treated with fibrates, versus 43.9 for controls (p\<0.001). For the combined endpoint of death or DR the respective rates were 51.2 and 63.4 events/1000 person-years (p\<0.001). [Figure 2](#BMJOPEN2013004025F2){ref-type="fig"} shows the Kaplan-Meier curves for each outcome. Of those coded with a retinopathy event, a majority in both groups had their first retinopathy event recorded as either background DR or retinopathy unspecified (95.1% fibrate treated vs 96.1% non-fibrate treated).

###### 

Crude event frequency and event rates for fibrate-exposed and non-exposed subjects

                                   Fibrate-exposed   Non-exposed                
  -------------------------------- ----------------- ------------- ----- ------ ---------
  All patients                                                                  
   Diabetic retinopathy            489               33.4          569   40.4   0.002
   Death                           295               18.1          312   19.8   0.297
   Death or diabetic retinopathy   740               50.6          847   60.2   \<0.001
  Patients with complete data                                                   
   Diabetic retinopathy            395               34.3          481   43.9   \<0.001
   Death                           228               17.9          238   19.2   0.421
   Death or diabetic retinopathy   589               51.2          695   63.4   \<0.001

![Kaplan-Meier (unadjusted) curves for time to clinical endpoints.](bmjopen2013004025f02){#BMJOPEN2013004025F2}

Adjusted survival {#s3c}
-----------------

After adjustment for baseline covariates and time-dependent HbA1c, time to DR was significantly greater for participants treated with fibrates, with an adjusted HR (aHR) of 0.785 (95% CI 0.688 to 0.896; p\<0.001) for those with a full dataset and 0.802 (0.710 to 0.905; p\<0.001) for all participants ([table 4](#BMJOPEN2013004025TB4){ref-type="table"}). For the combined endpoint of death or DR the aHRs were 0.783 (0.689 to 0.886; p\<0.001) for those with a full dataset and 0.799 (0.724 to 0.883; p\<0.001) for all participants. There was no difference for death alone: aHR=0.910 (0.760 to 1.090; p=0.305) and 0.889 (0.758 to 1.043; p=0.149) for those with a full dataset and for all participants, respectively.

###### 

Adjusted Cox models characterising progression to the respective clinical endpoints of newly diagnosed diabetic retinopathy and all-cause mortality

                                  Patients with complete data   All patients                                            
  ------------------------------- ----------------------------- -------------- ------- ------- -------- ------- ------- ---------
  Diabetic retinopathy            0.785\*                       0.688          0.896   0.000   0.802†   0.710   0.905   \<0.001
  Death or diabetic retinopathy   0.783‡                        0.689          0.886   0.000   0.799§   0.724   0.883   \<0.001

\*Baseline HbA1c, diabetes duration.

‡Age, gender, smoking status, baseline HbA1c, prior primary care contacts, diabetes duration and Charlson index.

†Time-dependent HbA1c, diabetes duration.

§Age, smoking status, prior primary care contacts, Charlson index, time-dependent HbA1c and diabetes duration.

aHR, adjusted HR; HbA1c, glycated haemoglobin.

HbA1c and progression to DR {#s3d}
---------------------------

HbA1c was modelled in three ways: as baseline values, time-dependent values and mean follow-up values. All three measures showed a general trend of increasing risk of DR with increasing HbA1c ([figure 3](#BMJOPEN2013004025F3){ref-type="fig"}).

![Glycated haemoglobin (HbA1c) and progression to diabetic retinopathy\*.](bmjopen2013004025f03){#BMJOPEN2013004025F3}

Discussion {#s4}
==========

Based on the current predictions, the diabetes pandemic will involve 552 million people, or 10% of the world\'s population by 2030, and in its wake the burden of complications is expected to increase.[@R14] It is estimated that worldwide there are approximately 93 million people with DR, of whom 28 million have sight-threatening DR.[@R1]

This article reports an approximate 20% reduction in rates of first retinopathy for patients treated with fibrate therapy. Based on real-world observational data, this supports the findings from randomised controlled trials. The FIELD DR study,[@R9] a randomised trial of monotherapy with 200 mg micronised fenofibrate per day, showed a significant reduction in the need for laser therapy for sight-threatening lesions of macular oedema and proliferative DR in the fenofibrate group compared with the placebo group (3.4% vs 4.9%; p\<0.001). In a subpopulation with central grading of fundus photographs using adapted Early Treatment Diabetic Retinopathy Study (ETDRS) criteria, progression of DR was significantly reduced in participants with DR (ETDRS level 20 or more) at baseline.

The ACCORD Eye study provided confirmatory evidence: fenofibrate (160 mg tablet per day, bioequivalent to the FIELD study\'s 200 mg micronized capsule) when added to a statin (simvastatin) slowed the progression of DR compared with simvastatin plus placebo, with an OR of 0.60 in the primary endpoint of three or more steps of progression on the ETDRS scale or a need for laser therapy or vitrectomy to treat proliferative DR.[@R10]

In neither the FIELD nor the ACCORD studies did the mechanism of the effect appear attributable to the observed changes in the circulating lipid profiles. Other clinical evidence linking dyslipidaemia and DR has been variable.[@R15; @R16; @R17; @R18; @R19] The impact of lipid-lowering therapy with statins has been shown to retard the progression of retinopathy in those with hypercholesterolaemia,[@R20] although a positive outcome has not always been evident.[@R21]

The mechanism(s) for the changes observed in this study may or may not be related to the lipid-lowering effects of fibrates.[@R22] While there is a little evidence to link the quantitative lowering of the major commonly measured circulating lipid fractions,[@R9] [@R10] qualitative changes may occur. Fibrates also cause an increase in apolipoprotein A1 (apoA1) expression, which could limit the lipotoxicity at the level of the retina, in addition to its inherent potent antioxidant and anti-inflammatory properties.[@R23; @R24; @R25]

Non-lipid-related mechanisms are currently regarded as the most plausible explanation for the beneficial effect of fibrate on DR. Fibric acid derivatives possess independent anti-inflammatory and antioxidant properties mediated by their proliferator-activated receptor-α (PPAR-α) agonist activity. Inflammation is decreased via inhibition of enhanced nuclear transcription factor-kappaB (NF-Kb) activity, thus preventing interleukin (IL)-1-induced expression of IL-6 and cyclo-oxygenase-2 and in turn preventing any increase in retinal capillary permeability at an early stage in the evolution of DR.[@R26] [@R27] Glucolipotoxicity-induced NF-kB activation can also increase the expression of the proinflammatory cytokine TNF-α, resulting in the upregulation of adhesion molecules, leucocyte and monocyte activation and vessel loss.[@R28] [@R29] Fenofibric acid is also known to prevent the disruption of retinal pigment epithelium (RPE) cells by the stress-induced cytokine IL-1β, achieved through the suppression of AMP-activated protein kinase activation.[@R30] In addition, further protection by fenofibric acid of the RPE may occur through the induction of autophagy and insulin-like growth factor-1 receptor mediated survival (antiapoptotic) pathways.[@R31] Fenofibric acid has also been demonstrated to prevent the increased breakdown of the blood--brain capillary barrier by lowering the overexpression of fibronectin and collagen IV basement membrane components of the RPE cells.[@R32] Fibric acid can also downregulate the expression of vascular endothelial growth factor receptor 2,[@R33] a key regulator of vascular regrowth in response to retinal hypoxia,[@R34] thus avoiding an excess neovascularisation resulting in proliferative DR.[@R35] [@R36] Fibrates, by virtue of their PPAR-α agonist properties, can induce the expression of nitric oxide synthase and decrease cellular adhesion molecules, thereby inhibiting NF-Kb and suppressing the genes that encode adhesion molecules.[@R37] They also possess neuroprotective properties.[@R38]

These cumulative observations could well explain the retardation in DR progression found in previous studies[@R9] [@R10] and the prevention of DR onset found in this study in participants with type 2 diabetes. Despite the initial and subsequent reversible elevation of creatinine during treatment with fenofibrate, a reduction in albuminuria and a slower decline in the estimated glomerular filtration rate (GFR) over 5 years are reassuring.[@R39] A greater estimated GFR preservation was seen in those with baseline hypertriglyceridaemia or dyslipidaemia compared with those without. In those on fenofibrate, benefit was also related to the lipid-lowering response.

This study has a number of limitations. Routine data such as CPRD is able to complement randomised controlled trials evidence as it is based on real-world experience in the populations who are receiving the treatment rather than highly selected patients who may be less morbid and more compliant with the treatment regimens under trial conditions. However, there may be issues concerning the data quality. In this particular study, the data lacked a sufficient granularity to allow progression to discrete stages of retinopathy to be adequately captured, and thus we used the criterion of progression from no recorded retinopathy to first event as our primary outcome.

Routine data sources will also include missing data and measurements taken with varying periodicity, sometimes involving key variables that may be important as covariates. We therefore compared the results from sets of exposed and non-exposed patients matched using two different techniques: the first requiring full data values for all the match criteria and the second allowing missing data values for systolic blood pressure and HbA1c, where participants were then matched with a control with the same missing data value. There was no substantial difference in the HRs observed in either set.

It is also accepted that there will be additional coding imperfections, lack of standardisation of biochemical measures (such as HbA1c) and variations between biochemical test centres. There is no reason to suppose that there was a coding bias between the exposed and non-exposed groups, but this should be considered as a potential bias in the interpretation of the results. Equally, confounding by indication will also be considered as a source of bias.

The patient ethnicity, known to impact on diabetes progression and outcome, was not systematically recorded within CPRD. Exposure to fibrates and to other lipid-lowering pharmacotherapies of interest can only be taken as an intention to treat on the part of the prescriber. Fenofibrate was the second most common prescribed fibrate in our study but with the longest duration of exposure. However, we have no data as to whether the patient actually filled the prescription at the pharmacy or, further, as to whether they took the medicine at the recorded dosage.

In conclusion, the evidence from most common-scale randomised studies (the FIELD and ACCORD Eye studies) supports the use of the fibric acid derivative fenofibrate as an adjunctive therapy to maintaining good glycaemic and blood pressure control, in an effort to prevent the progression and enhance the regression of DR in people with type 2 diabetes. These new data suggest that the introduction of fenofibrate may be valuable in preventing the expression of DR. Randomised studies are necessary to consolidate or refute these findings.
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